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Objectives: Living donor liver transplantation (LDLT) is an accepted treatment for patients with end-
stage liver disease. To minimize risk to the donor, left lobe (LL) LDLT may be an ideal option in adult LDLT.
Methods: This study assessed the outcomes of LL-LDLT compared with right lobe (RL) LDLT in adults
(1998–2010) as reported to the United Network for Organ Sharing (UNOS) Organ Procurement and
Transplantation Network (OPTN).
Results: A total of 2844 recipients of LDLT were identified. Of these, 2690 (94.6%) underwent RL-LDLT
and 154 (5.4%) underwent LL-LDLT. A recent increase in the number of LL-LDLTs was noted: average
numbers of LL-LDLTs per year were 5.2 during 1998–2003 and 19.4 during 2004–2010. Compared with
RL-LDLT recipients, LL-LDLT recipients were younger (mean age: 50.5 years vs. 47.0 years), had a lower
body mass index (BMI) (mean BMI: 24.5 kg/m2 vs. 26.8 kg/m2), and were more likely to be female (64.6%
vs. 41.9%). Donors in LL-LDLT had a higher BMI (mean BMI: 29.4 kg/m2 vs. 26.5 kg/m2) and were less
likely to be female (30.9% vs. 48.1%). Recipients of LL-LDLT had a longer mean length of stay (24.9 days
vs. 18.2 days) and higher retransplantation rates (20.3% vs. 10.9%). Allograft survival in LL-LDLT was
significantly lower than in RL-LDLT and there was a trend towards inferior patient survival. In Cox
regression analysis, LL-LDLT was found to be associated with an increased risk for allograft failure [hazard
ratio (HR): 2.39)] and inferior patient survival (HR: 1.86).
Conclusions: The number of LL-LDLTs has increased in recent years.
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Introduction
Living donor liver transplantation (LDLT) is currently an
accepted and standard procedure for the treatment of patients
with end-stage liver disease.1–3 The percentage of all liver trans-
plantations performed in the USA that use tissue from living
donors is < 10%, whereas > 40% of kidney transplantations use a
kidney sourced from a living donor. The slow rate of growth in
LDLT is mainly related to the associated risks for donors.2 Living
donor liver transplantation carries a higher risk for the donor than
live kidney donation.3 The risks specific to liver donation are at
least partially related to residual liver volume. Over the last several
years, the transplant community has focused mainly on minimiz-
ing risk for the donor and several studies have specifically focused
on methods of reducing the amount of liver removed from the
donor as a simple and easy way to decrease morbidity and mor-
tality risks for the donor.4–7 Because the left lobe represents a
markedly small percentage of the liver, it is assumed that removing
the left lobe from the donor implies a considerably lower risk
for liver failure or any other major complication in the donor.
However, few reports have analysed data on the impact of left lobe
transplantation for the recipient, patient survival and need for
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liver retransplantation.8–10 The aim of this paper was to analyse the
impact of allograft selection [left lobe (LL) vs. right lobe (RL)] on
outcomes in recipients after LDLT.
Materials and methods
Data were collected from the United Network for Organ Sharing
(UNOS) and refer to transplantations reported between 1998 and
2010. The following information on recipients in both the LL- and
RL-LDLT groups was collected: patient age; sex; Model for End-
stage Liver Disease (MELD) score; hospital length of stay; waiting
time prior to transplantation; body mass index (BMI); rejection at
1 year, and retransplantation rate. The following information on
donors was collected: age; weight; BMI, and sex. Missing values
were imputed with the mean values. The definition of small-for-
size syndrome was at the discretion of the centre.
Chi-squared and Student’s t-tests were used to compare pro-
portions and means, respectively. Graft and patient survival were
the primary outcomes measured. Kaplan–Meier analysis was used
for allograft and patient survival estimates. Continuous variables
were categorized using exploratory data analysis, and assumptions
of proportional hazards were met by extended Cox regression
models with time-dependent covariates. Variables for which
> 20% of values were missing were excluded from analysis. Ini-
tially, the following factors were included for unadjusted analysis:
recipient age; recipient sex; donor age; donor sex; diagnosis;
MELD score; length of stay; race, and acute rejection. An unad-
justed comparison of survival was performed using the log-rank
test. Hazard ratios (HRs) were estimated using Cox proportional
hazards methodology and estimates are reported as HR [95%
confidence interval (CI)]. Multivariate Cox modelling was per-
formed using potential risk factors and covariates found to be
statistically significant in unadjusted Cox models. Statistical sig-
nificance was indicated by a P-value of < 0.05.
This study was reviewed by the University of Massachusetts
Medical School Institutional Review Board (IRB) and deemed
appropriate for exemption from IRB oversight as no personal
identifiers were used among datasets.
Results
A total of 2844 patients underwent LDLT during the study period
(1998–2010); 2690 (94.6%) patients underwent RL-LDLT, and
154 (5.4%) underwent LL-LDLT. The demographic and clinical
characteristics of donors and recipients are shown in Table 1.
Preoperative MELD scores, wait times and rates of acute rejection
at 1 year were similar in both groups. Donor age was similar in
both groups, but donor weight and BMI were slightly higher in the
LL-LDLT group, which also included a higher percentage of male
donors. Compared with RL-LDLT patients, recipients of LL-LDLT
were younger (mean age: 50.5 years vs. 47.0 years), had a lower
BMI (mean BMI: 24.5 kg/m2 vs. 26.8 kg/m2), and were more likely
to be female (64.6% vs. 41.9%). Recipients of LL-LDLT had a
significantly longer mean length of stay (24.9 days vs. 18.2 days)
and a higher retransplantation rate (20.3% vs. 10.9%).
Allograft survival in both groups is shown in Fig. 1. Allograft
survival after RL-LDLT was better than that after LL-LDLT. In Cox
regression LL-LDLT was associated with an increased risk for
allograft failure (HR: 2.39) and patient death (HR: 1.86) (Table 2).
Surprisingly, there was an increase in the number of LL-LDLT
surgeries performed: the average number of LL-LDLTs performed
per year was 5.2 in 1998–2003 and 19.4 in 2004–2010 (P < 0.01)
(Fig. 2). Left lobe LDLT represented 2.3% of all LDLTs during
1998–2003 and 7.2% of all LDLTs in 2004–2010 (P = 0.01). The US
Table 1 Donor and recipient characteristics in right lobe (RL) and left lobe (LL) living donor liver transplantations (LDLTs) carried out in the
USA during 1998–2010
Variable RL-LDLT (n = 2690) LL-LDLT (n = 154) P-value
Donor age, years, mean  SD 38.8  10.2 37.1  10.1 NS
Donor weight, kg, mean  SD 77.4  16.9 80.1  16.3 0.02
Donor BMI, mean  SD 26.5  8.6 29.4  18.7 < 0.001
Donor gender, female, % 48.1% 30.9% 0.0008
Recipient age, years, mean  SD 50.5  7.1 47.0  6.9 < 0.001
MELD score, mean  SD 14.6  5.9 14.7  5.9 NS
LoS, days, mean  SD 18.2  21.9 24.9  26.1 < 0.001
Wait time, days, median 315.6  27.2 363.5  27.5 NS
Recipient weight, kg, mean  SD 78.5  17.1 68.3  17.6 < 0.001
Recipient BMI, mean  SD 26.8  5.0 24.5  4.4 < 0.001
Rejection at 1 year, % 17.1% 15.9% NS
Recipient gender, female, % 41.9% 64.6% < 0.001
Retransplantation, n (%) 255 (10.9%) 23 (20.3%) 0.0006
SD, standard deviation; BMI, body mass index in kg/m2; MELD, Model for End-stage Liver Disease; LoS, length of hospital stay; NS, not significant.
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experience in LL-LDLT was arbitrarily divided into two periods to
allow outcomes in the more recent period to be assessed. Interest-
ingly, there did not appear to be any improvement in the results
of LL-LDLT performed in 2007–2010 (n = 80) compared with
LL-LDLT performed in 1998–2006 (n = 74).
Discussion
Living donor liver transplantation was developed in response to a
severe shortage of deceased donors in the face of a growing list of
patients awaiting liver transplantation. The success of these pro-
cedures has led to the adoption of this technique around the
world, mainly in Asian countries, in response to the lack of avail-
ability of organs from deceased donors. However, LDLT remains
one of the most complicated surgical procedures and is associated
with relatively high rates of morbidity for both donor and
recipient.1–3 As a result, growth in the field remains slow compared
with that in living donor kidney transplantation. Currently, < 5%
of all liver transplantations involve living donors. This rate has
decreased over the last 10 years. In 2009, only 215 (3.7%) of 5795
liver transplants in adults were sourced from live donors.3
Living donor liver transplantation involves several issues that
are currently unsettled and the procedure itself is still evolving; the
complete resolution and standardization of these aspects would
probably lead to a noticeable increase in the number of LDLTs
performed. These issues refer to either donor- or recipient-
associated factors. Donor safety is the most compelling factor, but,
despite all measures implemented, to date over 20 live liver donors
have reportedly died and one is currently in a vegetative state.2,4
The outcome of the choice between the left and right lobes of the
liver may have an impact on liver-specific complication rates in
the donor5–15 because LL transplantation means that less liver
mass is removed, but it may not affect the rate of non-liver-related
complications. Umeshita et al. reported on the incidence of donor
complications based on 1853 donors recorded in the Japanese
Registry of LDLT.16 The incidence of complications was signifi-
cantly higher in RL donors than in donors of LL and lateral
segment grafts.16 Lo17 also reported the incidence of donor com-
plications based on a survey of 1508 transplantations performed
at five Asian centres. Again, complication rates were higher in RL
donors (28.0%) than in left lateral segment (9.3%) or LL (7.5%)
donors. Moreover, RL donors experienced more serious compli-
cations, such as cholestasis, bile leakage or stricture, portal vein
thrombosis, intra-abdominal bleeding and pulmonary embolism.
However, the difference between right and left lobe donation in
terms of recipient outcome has not been completely resolved.
Balancing donor safety with achieving a satisfying outcome for the
recipient is a key issue in the process of living donation. At the
start of adult LDLT, LL-LDLT was the only option available
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Figure 1 Kaplan–Meier analysis comparing (a) allograft and (b)
patient survival in left lobe (dashed line) and right lobe (continuous
line) living donor liver transplantation
Table 2 Cox proportional hazard model predicting allograft and
patient survival
Variables HR (95% CI) P-value
Allograft survival
Recipient age 1.01 (1.01–1.03) 0.0028
Recipient sex (female) 1.24 (1.01–1.54) 0.0380
LL-LDLT 2.39 (1.57–3.65) < 0.001
MELD score 1.10 (0.89–1.23) 0.1
Recipient BMI 1.01 (0.99–1.04) 0.07
Donor age 1.02 (1.01–1.03) < 0.001
Donor sex (female) 0.88 (0.71–1.07) 0.2
Patient survival
Recipient age 1.01 (1.01–1.04) < 0.001
Recipient sex (female) 1.23 (1.03–1.46) 0.01
LL-LDLT 1.86 (1.33–2.61) < 0.001
MELD score 1.12 (0.98–1.45) 0.25
Recipient BMI 1.08 (0.95–1.10) 0.09
Donor age 1.00 (0.99–1.05) 0.06
Donor sex (female) 0.78 (0.68–1.11) 0.3
HR, hazard ratio; 95% CI, 95% confidence interval; LL-LDLT, left lobe
living donor liver transplantation; MELD, Model for End-stage Liver
Disease; BMI, body mass index.
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because of the potential risk for the donor in RL-LDLT.8–10
However, the use of LL grafts in adults was severely limited by the
size limits of the LL. An initial report of 13 LL-LDLTs between
adults revealed satisfactory results in both donors and recipients,
with 11 of 13 patients surviving.18 Tanaka and Ogura reported an
early series of 39 LL-LDLTs in which survival was 82.1% in
patients with a graft : recipient weight ratio (GRWR) of  0.8 (n
= 28), but only 54.5% in those with a GRWR of < 0.8 (n = 11).19
Based on these unsatisfactory results, this team adopted the RL
graft in order to overcome size-related problems.19 Several
reports from single centres in the USA,7,20,21 Hong Kong,22
Europe23 and Japan24 have shown superior outcomes of RL-LDLT
in the recipient.
The present study found that donors in LL-LDLT were heavier
and recipients were lighter compared with RL-LDLT donors and
recipients, respectively. Although data on allograft weight were
not available in the database, it seems that the various transplant
programmes were very cautious about the size issue. The inferior
outcomes of LL-LDLT compared with RL-LDLT identified in this
study cannot be explained by graft size alone. Inflow and outflow
are also important to achieving successful outcomes in LDLT.
Several technical innovations have been implemented to deal with
venous outflow and high portal inflow in LDLT and have led to
great improvements in graft function.25–34 These techniques
include left portal and left hepatic vein shunts, hemiportocaval
shunt, splenic artery ligation or embolization, and venous outflow
modulation.25–34 These techniques are used to modulate portal
inflow to limit the negative effect of high flow in smaller grafts.
The theoretical advantage of these techniques on overall outcomes
in recipients of smaller grafts has not been widely studied and may
impact the choice between the left and right lobes. Botha et al.
showed that LL-LDLT using even smaller grafts (GRWR < 0.8) can
be performed safely with good outcomes by constructing a hemi-
portocaval shunt to prevent the development of small-for-size
syndrome while ensuring adequate liver volume.32
The most serious ethical concerns in LDLT focus on risk to the
donor and relate to the principle of ‘do no harm’. However,
restricting the focus to minimizing donor risk is not sufficient to
justify LL-LDLT ethically. Instead, Siegler et al. proposed a system
called ‘double equipoise’ in which the ethical acceptability of the
LDLT procedure would be determined by balancing donor risks
and benefits with recipient risks and benefits.35–37 Double equi-
poise should place clear limits on the morbidity and mortality
risks donors are allowed to assume and would stipulate that low
recipient benefit should discourage surgeons from allowing
donors to accept any risk associated with donation. Although left
hemiliver donation is clearly a safer operation for the donor,16,17
the present results suggest that LL-LDLT is not ready for wider
use based on recipient outcomes reported to UNOS. The recent
increase in the utilization of LL-LDLT did not show any improve-
ments in recipient outcomes over time. Left lobe LDLT is under-
going rapid evolution and is not yet ready for widespread use.
Although the transplant community is focused on improving
safety levels for live liver donors, overall outcomes in the recipient
should not be ignored, especially as the most recent data available
do not clearly define the true impact of the choice between the
right and left lobes on donor morbidity and mortality.
This study has several limitations. Firstly, it is a retrospective
analysis of UNOS data. There are both potential advantages
and limitations to any study that uses a large national database.
However, the large sample size provides sufficient power to detect
meaningful risk factors that may be missed by single-centre
studies. As with any analysis of data sourced from the UNOS
database, the present conclusions rely on the assumption that no
systematic bias has been generated by reporting error or missing
data. The groups are extremely unequal in size and the selection
criteria for one or the other procedure are not known. However,
the primary endpoints in this analysis were allograft and patient
survival, which are reliably captured in the UNOS database.
Residual or unmeasured confounders that might impact on
allograft and patient survival include: surgeon technique; dif-
ferences in immunosuppression protocols; the fat content and
quality of the allograft, and centre-specific practices. Data on
other important determinants of success in LDLT, such as recipi-
ent and donor selection, choice of RL vs. LL graft, graft weight and
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Figure 2 Numbers of (a) left lobe and (b) right lobe living donor liver
transplantations carried out in the USA (registered in the United
Network for Organ Sharing database) during 1998–2010
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quality, GRWR, surgical details, techniques employed to alleviate
small-for-size syndrome, and centre and surgeon volume and
experience, were not available in the database.
Secondly, few data on the donor and the quality or size of the
allograft were available. Thirdly, the study did not look at the
potential impact of portal inflow and hepatic vein outflow modu-
lation in smaller grafts. Fourthly, the study was unable to analyse
centre-specific outcomes.
In conclusion, the analysis of outcomes of LDLTs carried out in
the USA during 1998–2010 shows that outcomes of LL-LDLT were
inferior compared with those of RL-LDLT. The lower rate of graft
survival in LL-LDLT should be taken into consideration in the
overall debate regarding the choice of LL-LDLT vs. RL-LDLT.
Because LL donation may be associated with a lower rate of com-
plications in the donor, technical innovations, such as the modu-
lation of inflow and outflow in smaller grafts, should be studied
more carefully and may actually lead to the achieving of better
results in LL-LDLT. Given refinement of surgical procedures,
better graft selection, appropriate graft size matching and careful
recipient selection, LL-LDLT may achieve significant progress in
outcomes in the future. Left lobe LDLT should be performed
under protocol and studied to define the optimal outcomes in
experienced centres.
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